Introduction: de®nition of postoperative recurrence
There is little data presented in urological literature to help us decide between immediate and deferred hormone ablation in patients presenting with PSA failure after radical prostatectomy. Moreover, given the fragmentary and inclusive nature of the data that is published, it is worthwhile reviewing the de®nition of recurrence following radical prostatectomy. Recurrence can be de®ned in both biochemical and regional terms (e.g. local or distant). These include a postoperatively detectable serum PSA level ( b 0.2 ng/ml) for biochemical recurrence; palpable induration at the operative site and elevated serum PSA with or without a positive biopsy for local recurrrence; and positive bone scan or radiographic evidence of retroperitoneal adenopathy for distant recurrence.
To appreciate the extent of the problem associated with this de®nition, it is helpful to examine the data reported by Pound et al 1 in which a very selective series of 1623 patients undergoing radical retropubic prostatectomy were followed up for an average of 5 y. Of these patients, 17.0% were reported to show disease progression, while only 7.9% had detectable PSA levels, de®ned as b 0.2 ng/ml. This appears only to confound the matter, with con¯ict-ing results shown for clinical disease progression vs presence of detectable PSA levels.
Staging problems and prognostic factors for disease progression
When performing radical prostatectomy on a patient with clinically localized prostate cancer, the surgeon knows there is at least a 30 ± 60% chance of the cancer not being pathologically con®ned. In addition, at the moment, there are no staging methods available which can identify the pathological stage of the disease with absolute certainty. Hence, it is very dif®cult to select candidates for immediate adjuvant therapy to prevent and/or delay progression of their tumors.
However, it is known that higher recurrence rates are associated with a number of risk factors. These include multiple positive surgical margins, a high Gleason score (b 7) and a PSA 10 ng/ml before prostatectomy. Of course, pathological examination of specimens can give very important information allowing an objective prognosis. For example, it is known that there is a close relationship between pathological staging and future development of the tumour.
Recent data from Catalona and Smith 2 on the 7 y probability of non-progression shows that it is 81% for pT1 or pT2, but this drops to 57% for pT3a/b accompanied by positive margins, and is as low as 19% when lymph node metastases are present.
The Gleason score is also helpful, given the fact that there is a signi®cant difference in progression between tumors depending on their scores ( Table 1 ). The preoperative PSA is also of great importance as the probability of non-progression varies between patients depending on their preoperative values ( Table 2) .
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Data adapted from Catalona and Smith. routine follow-up is often the ®rst indication that treatment may be failing. It has been shown that PSA recurrence either precedes or occurs in conjunction with local or distant tumor progression. However, absence of a detectable serum PSA level does not rule out metastatic disease in every case. It was shown in a study by Lowe and Leiberman 3 that there is also a correlation between the mean time to PSA detection and the pathological stage of the disease (Table  3) . Thus, the more severe the stage, the shorter the time until the PSA level becomes detectable. Hardly surprisingly, it was also shown that there is a connection with the time of follow-up in severe cases with PSA recurrence seen in just under 34% of pT3a patients followed for b 2 y, and in 41% of those followed for b 3 y.
An interactive session at the EAU: clinical case studies At a workshop held as part of the European Association of Urology in Barcelona in 1998 a clinical case was presented of a 50-y-old man who had undergone radical prostatectomy, and in whom a biopsy showed a pT3a N0 M0, Gleason score 7 prostate carcinoma with a positive surgical margin. When the audience was asked how they would treat him, the majority (50%) decided on watchful waiting, while hormonal therapy received less than a quarter of the vote (17%). The patient himself did not want any adjuvant treatment, opting for a strategy of watchful waiting.
As a follow-up case study, his PSA level was presented as remaining undetectable for the next 3 y, rising slightly during the fourth year to 1.8 ng/ml. The audience was then asked again how they would treat the patient. This time there was a much greater spectrum of opinions and the number opting for watchful waiting was almost half the previous number, with 25% choosing local radiotherapy. The number choosing hormonal therapy remained steady at 17%. This relatively straightforward case study illustrates the dif®culty experienced within the urological community in identifying the best treatment strategy.
Rationale for early androgen deprivation therapy
Despite all this controversy, there are a number of theoretical reasons for introducing early androgen deprivation following a radical prostatectomy in patients presenting with`negative' prognostic factors. Myers et al 4 summed these up as follows:
The remaining cancer cell population may be (a) eradicated by early androgen deprivation produced by endocrine therapy or (b) reduced to dormant rests of undetectable cells which are unable to replicate or (c) reduced to non-dormant rests of initially undetectable cells able to replicate slowly.
Adolfsson and Tribukait 5 carried out repeated ®ne-needle biopsies in untreated patients with prostate cancer, showing that`progressive cytological dedifferentiation with respect to nuclear DNA ploidy occurs with shifts over time from diploid to nondiploid'.
Following this observation, Myers showed that growth factors, elaborated by androgen-responsive cells, stimulate the growth and survival of androgen-independent cells, and suggested that endocrine therapy should be started as soon as possible because of its growth-inhibitory effect on androgen-independent cells. He also warned that the continued growth of presumably residual diploid cancer that is not exposed to early endocrine therapy may result in subsequent mutations or the outgrowth of resistant cancer cells.
The UK Medical Research Council Prostate Cancer Working Party Investigators Group 6 described in 1997 a subset of locally advanced or asymptomatic metastatic prostate cancer patients who were randomized to either immediate treatment (with orchiectomy or GnRH analogs) or deferred therapy until an indication presented. They found that progression of disease was arrested or retarded in the group receiving immediate treatment.
However, not everyone seems to agree with this ®nd-ing, as shown in Lowe's paper published in the same year, which reads,`The prolonged disease-free interval seen in the majority of patients with pT3 with PSA recurrence seems to be a strong indicator that immediate intervention may not be necessary without other evidence of disease progression. ' Thus, today, urologists appear to have two different subsets of patients for possible hormonal management. The ®rst group comprises those presenting with favourable prognostic factors after radical prostatectomy (i.e. those with a pathologically localized cancer who were not treated initially on the assumption that the tumour had been eradicated by surgery). The second group consists of those presenting with unfavourable prognostic factors (e.g. pT3 patients with positive surgical margins, a high Gleason score, and a high pre-operative PSA, who were not treated initially). There can even be a third subset consisting of those who, following radical prostatectomy and subsequent adjuvant radiotherapy, may present with a rising PSA.
When PSA levels start to rise in each of these three groups, we have to decide whether or not to initiate androgen deprivation. In our hospital, we believe that additional treatment should be offered only to patients who exhibit a shorter PSA-doubling time, and withheld from those with longer doubling times until they present other evidence of local or distant progression. 
Clinician's dilemma
With all these arguments still far from being conclusive, in the PSA era, urologists appear to be faced with the dilemma between treating and holding off on patients with a rising PSA. This situation is often confounded by the psychological pressure from the patient to treat. What are really needed are prospective, randomized studies to give urologists suf®cient evidence to end this dilemma. There are currently no conclusive, randomized studies published to help us with these decisions, and the prospects of future studies continues to be bleak with the recent closing of a European cooperative study after a recruitment period of 1 y failed to enroll a suf®cient number of patients.
